AVTX
Avalo Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$19.23
+1.21%Next report
Analyst consensus
- Next report date
- Nov 5, 2026
- EPS estimate
- -$0.56
- Revenue estimate
- —
Latest reported
- Last report date
- Aug 6, 2026
- EPS actual
- -$0.83
- EPS estimate
- -$0.58
- Revenue actual
- —
- Revenue estimate
- —
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 6
- EPS misses (12Q)
- 6
- EPS in line (12Q)
- 0
- Avg surprise (4Q)
- +1.1%
- Revenue beats (12Q)
- 2
Analyst ratings
Sell-side consensus
- Consensus
- Buy
- Price target
- $42
- PT range
- $30 – $58
- Analysts
- 5
5 Buy0 Hold0 Sell
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Nov 5, 2026